Becton Dickinson
BDX
$212.78
+0.05%
Becton, Dickinson and Company (BDX) is a global medical technology company that manufactures and sells a broad portfolio of medical devices, instrument systems, and reagents, organized into four segments following the separation of its life science business: Medical Essentials (catheters, syringes, infection prevention), Connected Care (Alaris infusion pumps, Pyxis dispensing, pharmacy automation), Biopharma Systems (prefillable syringes and autoinjectors), and Interventional (surgery, peripheral vascular, urology), with more than 60% of revenue generated in the United States. As one of the largest and most entrenched players in medical instruments and supplies, BDX is a scale-driven, hospital- and pharma-supplier platform whose competitive moat rests on deep customer relationships, regulatory approvals, and a razor-and-blade installed base in medication management and injection devices. The current investor narrative centers on the post-life-sciences-separation portfolio reshaping, a sharp margin and earnings recovery visible in the fiscal Q4 2026 results (EPS of $2.55, gross margin of 51.1%), and a management-led profit outlook hike paired with a new CFO appointment announced in May 2026. Debate is split between bulls who see a re-rating story as profitability normalizes after a loss-making fiscal Q2 and bears who point to a 10.5% year-over-year revenue decline in the latest quarter, a stretched dividend payout ratio above 100%, and lingering skepticism reflected in a mixed analyst tape.…
BDX
Becton Dickinson
$212.78
Related headlines
Investment Opinion: Should I buy BDX Today?
Rating: Hold, with a constructive bias. The core thesis is that BDX has already re-rated on a genuine, quantified margin and earnings inflection — gross margin from 45.7% in Q2 2026 to 51.1% in Q4, operating margin from 1.99% to 19.6%, and Q4 EPS of $2.55 versus a Q2 loss of $1.11 — but at $218.03 the stock sits just 0.8% below its 52-week high of $219.78 and only ~3.7% below the $226.14 average analyst target, so the easy money has been made. The consensus 'buy' (9 Buy, 6 Hold, 1 Sell; mean 2.0) supports staying invested, but the thin implied upside argues against adding aggressively at current levels.
Supporting evidence is genuinely mixed but leans positive on profitability and negative on the top line. The forward PE of 15.3x on $17.42 estimated EPS is roughly 20-30% below the high-teens to low-20s typical of healthcare supplies peers, and EV/EBITDA of 14.2x, PS of 2.56x, and P/B of 2.02x all sit at or below the low end of BDX's own multi-year band (PS ran 7.2x-12.4x in 2022-2025). Free cash flow of $2.768 billion is ~5.6% of the $49.8 billion market cap, and Q4 operating cash flow of $1.46 billion plus $2.5 billion of Q3 buybacks confirm real cash conversion. Against that, Q4 revenue fell 10.5% year over year to $5.274 billion, the 101.3% payout ratio means the 2.33% dividend is not yet covered by earnings, and the current ratio of 0.87 with debt-to-equity of 0.66 leaves limited balance-sheet cushion.
The biggest risks that could invalidate the thesis are (1) revenue failing to return to the $22.9 billion consensus, which would make 15.3x forward a value trap rather than a discount; (2) margin normalization stalling below the 19.6% Q4 operating margin as one-time charges roll off unevenly; and (3) a dividend reset if free cash flow coverage does not improve. This Hold would upgrade to Buy on a pullback toward the $195-$200 zone (near the analyst low target, implying ~10% downside) or on a clean breakout above $219.78 accompanied by a return to positive year-over-year revenue growth; it would downgrade to Sell if revenue declines persist into fiscal 2027 or if the payout ratio stays above 100% for another two quarters. Valuation verdict: fairly valued to modestly undervalued versus BDX's own history and peers, but not undervalued enough to compensate for the top-line uncertainty at a price pinned near the 52-week high.
Sign up to view all
BDX 12-Month Price Forecast
BDX presents a credible but largely priced-in recovery: the margin and earnings inflection is real and quantified, and the 15.3x forward multiple is undemanding if the $17.42 EPS estimate holds, but the 10.5% revenue decline and 101.3% payout ratio mean the top line must cooperate for the discount to close. Analyst sentiment is constructive (9 Buy, 6 Hold, 1 Sell; mean 2.0) yet the $226.14 average target offers only ~3.7% upside, and the $195-$242 range spanning ~24% reflects genuine disagreement about the recovery's magnitude. A beta of 0.28 and relative strength of +49.8 points over six months support holding through volatility, but the stock's position near its 52-week high of $219.78 limits near-term risk/reward. I would upgrade to bullish on a pullback toward $195-$200 or on evidence of positive year-over-year revenue growth, and downgrade to bearish if revenue declines persist into fiscal 2027 or the payout ratio stays above 100% for another two quarters.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $226.14 and implied upside of +6.3% versus the current price.
Average Target
$226.14
16 analysts
Implied Upside
+6.3%
vs. current price
Analyst Count
16
covering this stock
Price Range
$195 - $242
Analyst target range
Coverage is solid with 14 analysts, and the distribution of 9 Buy, 6 Hold, and 1 Sell produces a consensus recommendation of "buy" (mean score 2.0 on a 1-5 scale). The average target price of $226.14 implies about 3.7% upside from the current $218.03, a modest gap that reflects how much of the recovery is already priced in after the stock's 15.4% one-month surge; the consensus leans constructive but not aggressively bullish, consistent with the mixed institutional tape. Notably, the forward EPS estimate of $17.42 and revenue estimate of $22.9 billion underpin the targets, and the recent November 6 actions were mostly reiterations with one upgrade (Wells Fargo to Overweight from Equal Weight), suggesting analysts are warming to the story without yet chasing it.
The target range of $195.00 to $242.00 is moderately wide, spanning about 24% from low to high, which signals meaningful disagreement about the earnings recovery's magnitude. The high target of $242 (roughly 11% above the current price) likely assumes successful margin normalization toward the high-teens operating margin seen in Q4, revenue returning to growth near the $22.9 billion consensus, and multiple expansion as the payout ratio normalizes; the low target of $195 (about 11% below current) likely prices in revenue stagnation, continued margin pressure, and dividend coverage concerns. The presence of a Barclays Underweight reiteration on November 10 and multiple Neutral/Sector Perform ratings from JP Morgan, Piper Sandler, and RBC indicates the bear case is alive, and the wide spread plus the stock's low beta of 0.28 means the risk/reward is balanced rather than compelling at current levels.
Bulls vs Bears: BDX Investment Factors
The bull case currently has the stronger evidence: the margin and earnings inflection is real and quantified (gross margin 45.7% to 51.1%, operating margin 1.99% to 19.6% from Q2 to Q4), the 15.3x forward PE is undemanding versus peers, and relative strength of +49.8 points over six months confirms genuine institutional demand. The bear case is not weak, however — a 10.5% revenue decline, a 101.3% payout ratio, and only ~3.7% upside to the average target mean the recovery is largely priced after a 15.4% one-month surge. The single most important tension is whether revenue returns to the $22.9 billion consensus: if top-line growth resumes, the forward multiple re-rates and the $242 high target becomes reachable; if revenue stagnates, the 15.3x forward PE is a value trap and the $195 low target comes into play. With a beta of 0.28 and the stock pinned near its 52-week high, the setup is balanced-to-positive but not compelling at current levels.
Bullish
- Sharp margin and earnings inflection: Gross margin expanded from 45.7% in Q2 2026 to 46.5% in Q3 and 51.1% in Q4, while operating margin recovered from 1.99% to 19.6% over the same span. Q4 EPS of $2.55 and net income of $696 million reversed the Q2 loss of $311 million (EPS -$1.11), showing the impairment-driven trough is behind the company.
- Forward multiple undemanding at 15.3x: The stock trades at 43.6x trailing EPS of roughly $5.01 but only 15.3x forward EPS of $17.42, a ~65% compression that prices a full earnings normalization. That forward multiple sits roughly 20-30% below the high-teens to low-20s typical of healthcare supplies peers, leaving room for re-rating if estimates hold.
- Powerful relative strength vs. market: BDX is up 15.4% over one month versus SPY's -2.26% (relative strength +17.7 points) and 52.0% over six months versus SPY's 2.13% (+49.8 points). The stock sits at ~98% of its 52-week range ($140.11-$219.78), signaling institutional accumulation rather than a fading bounce.
- Analyst consensus constructive with upgrade tape: Coverage of 14 analysts splits 9 Buy, 6 Hold, 1 Sell for a consensus 'buy' (mean 2.0), with an average target of $226.14 implying ~3.7% upside. Wells Fargo's upgrade to Overweight on November 6 and the May 2026 profit outlook hike plus new CFO appointment suggest sentiment is warming.
Bearish
- Revenue declining 10.5% year over year: Fiscal Q4 2026 revenue of $5.274 billion fell 10.5% from $5.890 billion in Q4 2025, and the trailing four-quarter run-rate of ~$20.2 billion sits below the prior-year comparable. The bull case hinges on revenue returning to the $22.9 billion consensus, which requires a sharp reversal of the current top-line trajectory.
- Dividend payout ratio above 100%: The 2.33% dividend yield carries a 101.3% payout ratio, meaning the dividend is being funded partly from balance-sheet capacity rather than earnings. Until free cash flow coverage improves, this caps multiple expansion and raises the risk of a dividend policy reset.
- Thin analyst upside already priced in: The $226.14 average target implies only ~3.7% upside from $218.03 after the stock's 15.4% one-month surge, and the $195 low target sits ~11% below current price. With the stock at ~98% of its 52-week range, much of the recovery appears discounted, limiting risk/reward.
- Leverage and tight liquidity: Debt-to-equity of 0.66 and a current ratio of 0.87 (below 1.0) indicate a leveraged, working-capital-tight structure, with interest coverage of 7.9x and cash-flow-to-debt of 0.089 leaving limited cushion. Trailing ROE of 4.6% and net margin of 5.9% remain far below a mature medtech franchise's norms.
BDX Technical Analysis
BDX is in a powerful, sustained uptrend, with the stock up 12.9% over the past year and an extraordinary 52.0% over six months, and at a current price of $218.03 it is trading at roughly 98% of its 52-week range (low $140.11, high $219.78), essentially pinned to all-time-high territory. That positioning signals strong momentum and institutional accumulation rather than overextension, particularly because the advance has been orderly and stair-stepped rather than parabolic; the max drawdown of -33.0% over the trailing period underscores that this recovery was earned from a deep prior trough. The stock is knocking on the door of its 52-week high, and a clean breakout above $219.78 would confirm the trend and likely invite momentum-driven flows.
Short-term momentum is accelerating and decisively diverging from the broader market: BDX is up 15.4% over the past month versus a -2.26% decline in SPY, a relative strength of +17.7 points, and up 18.9% over three months against SPY's -2.83% (relative strength +21.7). The 1-month gain (15.4%) is nearly matching the entire 1-year gain (12.9%), which tells us the move is front-loaded and recent rather than a slow grind, and the 6-month relative strength of +49.8 points confirms persistent outperformance. This is not a mean-reversion setup but a genuine trend acceleration, likely catalyzed by the November 5 fiscal Q4 print and the subsequent analyst actions; the risk is that such a steep one-month surge leaves the stock vulnerable to profit-taking, and the elevated short ratio of 5.07 suggests some positioning friction that could amplify either direction.
Key technical levels are well defined: support sits at the 52-week low of $140.11, roughly 36% below the current price, with intermediate support likely in the $180-$190 zone where the stock consolidated through September and October; resistance is the 52-week high of $219.78, just 0.8% above the current $218.03. A breakout above $219.78 would signal a new leg higher and validate the re-rating thesis, while a breakdown below $180 would break the sequence of higher lows and flag trend exhaustion. Volatility is unusually low for an equity: the beta of 0.28 means BDX moves roughly 72% less than the market, which supports larger position sizing for risk-parity allocators but also means the recent 15% monthly move is a genuine outlier relative to its own historical behavior and warrants attention.
Beta
0.28
0.28x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$140-$220
Price range past year
Annual Return
+12.2%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | +9.5% | -9.7% |
| 3m | +10.8% | -9.9% |
| 6m | +44.1% | -7.5% |
| 1y | +12.2% | +4.7% |
| ytd | +9.2% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
Revenue is the weak spot in an otherwise improving story: fiscal Q4 2026 revenue of $5.274 billion declined 10.5% year over year from $5.890 billion in Q4 2025, and the trailing four-quarter run-rate of roughly $20.2 billion ($5.274B + $4.983B + $4.714B + $5.252B) sits below the prior-year comparable. The sequential trend is more encouraging, with revenue rising from $4.714 billion in Q2 to $4.983 billion in Q3 and $5.274 billion in Q4, suggesting the year-over-year decline reflects portfolio changes and prior-year comparatives rather than demand deterioration. Segment disclosure remains thin (Medical at $2.4 billion and Life Sciences at $2.5 billion), but the analyst consensus revenue estimate of $22.9 billion for the forward year implies a return to growth, which is the linchpin of the bull case.
Profitability has inflected sharply and is the core of the re-rating: Q4 2026 net income of $696 million and diluted EPS of $2.55 compare with a loss of $311 million (EPS -$1.11) in Q2 2026, and gross margin expanded from 45.7% in Q2 to 46.5% in Q3 and 51.1% in Q4, while operating margin recovered from 1.99% in Q2 to 19.6% in Q4. The full-year picture is muddied by the Q2 impairment-driven loss, leaving trailing net margin at just 5.9% and ROE at 4.6%, well below what a mature medtech franchise should deliver. The trajectory, however, is clearly toward normalization, and the forward EPS estimate of $17.42 versus trailing EPS of roughly $5.01 (a 43.6x trailing PE) implies the market expects a dramatic earnings step-up as one-time charges roll off and margins settle in the high-teens to low-20s.
Balance sheet and cash flow are adequate but not pristine: debt-to-equity of 0.66 and a current ratio of 0.87 (below 1.0) indicate a leveraged, working-capital-tight structure, while trailing free cash flow of $2.768 billion against a $49.8 billion market cap yields about 5.6%, a respectable but not exceptional cash return. Interest coverage of 7.9x and a cash-flow-to-debt ratio of 0.089 show the company services its obligations comfortably but has limited cushion, and the dividend payout ratio of 101.3% means the $0.0233 yield (2.33%) is currently being funded partly from balance-sheet capacity rather than pure earnings. ROA of 3.6% and ROE of 4.6% are depressed by the impairment year, but the Q4 operating cash flow of $1.46 billion and FCF of $1.164 billion demonstrate the underlying business generates real cash, and the $2.5 billion of buybacks executed in Q3 signal management confidence in the recovery.
Quarterly Revenue
$5.3B
2026-09
Revenue YoY Growth
-10.5%
YoY Comparison
Gross Margin
51.1%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Because trailing net income is positive but heavily distorted by the Q2 impairment, I lead with the forward PE as the most informative metric: the stock trades at 43.6x trailing earnings but only 15.3x forward EPS of $17.42, a roughly 65% compression that tells you the market is pricing a full earnings normalization rather than extrapolating the depressed trailing figure. The trailing PE of 43.6x on EPS of about $5.01 is essentially meaningless as a valuation anchor given the one-time charges, so the forward multiple is the correct lens, and at 15.3x it is undemanding for a large-cap medtech franchise if the earnings recovery materializes.
On the other multiples, BDX looks inexpensive relative to its own history and to typical medtech peers: price-to-sales of 2.56x, price-to-book of 2.02x, EV/EBITDA of 14.2x, and EV/sales of 3.86x are all at or below the low end of the company's multi-year band, where historical PS ratios ran as high as 9-12x in 2022-2024 and PE ratios ranged from 17x to over 40x. The PEG ratio of -1.47 is not meaningful given the negative earnings base, and the 2.33% dividend yield with a 101% payout ratio is a yellow flag that caps multiple expansion until free cash flow coverage improves. Relative to a healthcare supplies sector that typically trades in the high-teens to low-20s forward PE, BDX's 15.3x forward multiple represents a discount of roughly 20-30%, which the market is justifying with the revenue decline and payout-ratio strain.
Historically, the current valuation sits near the bottom of BDX's own range: the PS ratio of 2.56x compares with 7.2x-12.4x across 2022-2025, and the price-to-book of 2.02x is near the low end of its 1.5x-2.4x band, while the forward PE of 15.3x is well below the 17x-49x trailing range of the past several years. This positioning suggests the market is pricing in skepticism about the durability of the earnings recovery and the revenue trajectory, which creates asymmetric upside if the forward estimates prove conservative, but it also reflects genuine fundamental deterioration in the top line that must reverse for the discount to close.
PE
43.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 17x~49x
vs. Industry Avg
40.3x
Industry PE ~40.3x*
EV/EBITDA
14.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the top line and dividend coverage. Revenue fell 10.5% year over year in Q4 2026 to $5.274 billion, and the trailing four-quarter run-rate of ~$20.2 billion is below the prior-year comparable, so the forward $22.9 billion consensus requires a sharp reversal. The 101.3% payout ratio means the 2.33% dividend is partly funded from balance-sheet capacity, and with a current ratio of 0.87, debt-to-equity of 0.66, and cash-flow-to-debt of just 0.089, there is limited cushion if cash flow disappoints. Trailing ROE of 4.6% and net margin of 5.9% remain depressed by the Q2 impairment, so the earnings recovery must be delivered, not just forecast.
Market and competitive risks revolve around valuation and sentiment. At 15.3x forward EPS of $17.42 the stock is cheap versus peers, but that discount is justified by the revenue decline and payout strain — if growth does not return, the multiple stays compressed. The stock is up 15.4% in one month versus SPY's -2.26% and sits at ~98% of its 52-week range, leaving it vulnerable to profit-taking, and the elevated short ratio of 5.07 could amplify a pullback. A beta of 0.28 limits macro-driven downside but also means the recent surge is an outlier relative to the stock's own behavior; the Barclays Underweight reiteration on November 10 and Neutral ratings from JP Morgan, Piper Sandler, and RBC show skepticism persists.
In a worst-case scenario, revenue fails to return to the $22.9 billion consensus, margin normalization stalls below the high-teens operating margin seen in Q4, and the payout ratio forces a dividend reset — triggering analyst downgrades and multiple compression toward the $195 low target, about 11% below the current $218.03. A deeper de-rating toward the 52-week low of $140.11 would represent roughly a 36% loss from current levels, consistent with the -33.0% max drawdown already experienced over the trailing period. The realistic downside band is therefore -11% to -36%, with the low end requiring both an earnings miss and a sentiment reversal.
FAQ
The most severe risk is top-line stagnation: Q4 2026 revenue fell 10.5% year over year to $5.274 billion, and the $22.9 billion forward consensus requires a sharp reversal, so failure here turns 15.3x forward into a value trap. Second is dividend coverage — the 101.3% payout ratio means the 2.33% yield is partly funded from balance-sheet capacity, and with a current ratio of 0.87 and debt-to-equity of 0.66 there is limited cushion for a reset. Third is margin durability: the 51.1% gross and 19.6% operating margins in Q4 must be sustained as one-time items roll off, or the earnings recovery narrative breaks. Fourth is positioning and sentiment — the stock is up 15.4% in one month versus SPY's -2.26%, sits at ~98% of its 52-week range, and carries a 5.07 short ratio that could amplify a pullback, with Barclays' November 10 Underweight reiteration showing the bear case remains live.
The 12-month forecast splits into three scenarios: a 55% base case of $220-$232 (grinding toward the $226.14 average target as $17.42 forward EPS is delivered and the multiple holds at 13x-15x), a 25% bull case of $235-$242 (revenue returns to the $22.9 billion consensus, gross margin holds above 50%, and the multiple re-rates toward high-teens to low-20s peers), and a 20% bear case of $195-$205 (revenue stagnation, margin normalization stalling, and a dividend credibility hit driving compression toward the $195 low target). The base case is most likely, and its key assumption is that forward EPS of $17.42 is broadly achieved with Q4-level margins proving repeatable while revenue stabilizes near consensus. The $195-$242 range spans about 24%, reflecting genuine analyst disagreement, and the 9 Buy/6 Hold/1 Sell split with a mean rating of 2.0 supports a constructive but not aggressive stance.
BDX screens modestly undervalued on forward earnings but fairly valued on almost everything else. The 43.6x trailing PE is distorted by the Q2 impairment and should be ignored; the meaningful figure is 15.3x forward EPS of $17.42, roughly 20-30% below the high-teens to low-20s typical of healthcare supplies peers. Price-to-sales of 2.56x, price-to-book of 2.02x, EV/EBITDA of 14.2x, and EV/sales of 3.86x all sit at or below the low end of BDX's own multi-year band, where PS ran 7.2x-12.4x in 2022-2025. The market is therefore pricing skepticism about the durability of the earnings recovery and the revenue trajectory, not paying a premium. That leaves room for re-rating if the $22.9 billion revenue consensus and $17.42 EPS are delivered, but the 101.3% payout ratio caps how far the multiple can expand until free cash flow coverage improves.
From a risk/reward standpoint BDX is a reasonable hold but a mediocre fresh entry at $218.03. The upside to the $226.14 average analyst target is only about 3.7%, while the $195 low target implies roughly 11% downside and the 52-week low of $140.11 implies about 36% downside, so the payoff is asymmetric in the wrong direction at current levels. The quality of the franchise is not in question — Q4 gross margin of 51.1% and operating margin of 19.6% show a real profitability inflection, and 15.3x forward EPS of $17.42 is cheap versus high-teens to low-20s peer multiples. But the 10.5% year-over-year revenue decline and 101.3% payout ratio mean the discount is earned, not a mispricing. It is a good buy for defensive, low-beta (0.28) investors on a pullback toward $195-$200, or for those willing to wait for evidence of positive revenue growth; it is a poor buy for anyone chasing the 15.4% one-month surge near the 52-week high.
BDX is better suited to a long-term holding period of at least 12-18 months than to short-term trading. The beta of 0.28 means it moves roughly 72% less than the market, which is unattractive for traders seeking volatility but valuable for risk-parity allocators and defensive portfolios, and the 2.33% dividend yield adds a modest income component despite the 101.3% payout ratio. The recovery thesis is a multi-quarter earnings normalization story — trailing EPS of about $5.01 versus a $17.42 forward estimate implies the step-up unfolds over several reporting periods, not weeks. Short-term traders face poor odds: the stock is up 15.4% in one month and sits at ~98% of its 52-week range, leaving little room before resistance at $219.78 and meaningful downside toward the $195 low target. A concrete minimum holding period of 12-18 months allows time for fiscal 2027 revenue to either validate or refute the consensus, and for dividend coverage to normalize.

